...
首页> 外文期刊>Bioorganic and medicinal chemistry >Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: Identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones
【24h】

Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: Identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones

机译:新型席夫碱对碳酸酐酶同工型I,II,IX和XII的抑制作用:与细胞溶质同工型的肿瘤相关同工型的选择性抑制剂的鉴定

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A series of new Schiff bases was obtained from sulfanilamide, 3-fluorosulfanilamide or 4-(2-aminoethyl)benzenesulfonamide and aromatic/heterocyclic aldehydes incorporating both hydrophobic and hydrophilic moieties. The obtained sulfonamides were investigated as inhibitors of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the cytosolic CA I and II, as well as the transmembrane, tumor-associated CA IX and XII. Most derivatives were medium potency or weak hCA I/II inhibitors, but several of them showed nanomolar affinity for CA IX and/or XII, making them an interesting example of isoform-selective compounds. The nature of the aryl/hetaryl moiety present in the initial aldehyde was the main factor influencing potency and isoform selectivity. The best and most CA IX-selective compounds incorporated moieties such as 4-methylthiophenyl, 4-cyanophenyl-, 4-(2-pyridyl)-phenyl and the 4-aminoethylbenzenesulfonamide scaffold. The best hCA XII inhibitors, also showing selectivity for this isoform, incorporated 2-methoxy-4-nitrophenyl-, 2,3,5,6-tetrafluorophenyl and 4(2-pyridyl)-phenyl functionalities and were also derivatives of 4-aminoethylbenzenesulfonamide. The sulfanilamide and 3-fluorosulfanilamide derived Schiff bases were less active compared to the corresponding 4-aminoethyl-benzenesulfonamide derivatives. As hCA IX/XII selective inhibition is attractive for obtaining antitumor agents/diagnostic tools with a new mechanism of action, compounds of the type described here may be considered interesting preclinical candidates. (C) 2014 Elsevier Ltd. All rights reserved.
机译:从磺胺,3-氟磺胺或4-(2-氨基乙基)苯磺酰胺和结合了疏水和亲水部分的芳族/杂环醛获得了一系列新的席夫碱。研究了获得的磺酰胺作为四种生理相关的碳酸酐酶(CA,EC 4.2.1.1)同工型,胞质CA I和II以及跨膜,与肿瘤相关的CA IX和XII的抑制剂。大多数衍生物是中等强度的或较弱的hCA I / II抑制剂,但其中一些显示出对CA IX和/或XII的纳摩尔亲和力,这使其成为同工型选择性化合物的有趣例子。起始醛中存在的芳基/杂芳基部分的性质是影响效价和同工型选择性的主要因素。最好和最多的CA IX选择性化合物结合了部分,例如4-甲硫基苯基,4-氰基苯基-,4-(2-吡啶基)-苯基和4-氨基乙基苯磺酰胺骨架。最好的hCA XII抑制剂,也显示出对该同种型的选择性,并结合了2-甲氧基-4-硝基苯基-,2,3,5,6-四氟苯基和4(2-吡啶基)-苯基官能团,并且是4-氨基乙基苯磺酰胺的衍生物。与相应的4-氨基乙基-苯磺酰胺衍生物相比,由磺胺和3-氟磺酰胺衍生的席夫碱的活性较低。由于hCA IX / XII选择性抑制对于获得具有新作用机制的抗肿瘤药/诊断工具具有吸引力,因此此处所述类型的化合物可能被认为是有趣的临床前候选药物。 (C)2014 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号